TRIPLE NEGATIVE BREAST NEOPLASMS

This study tested whether adding the immunotherapy drug avelumab after standard treatment (surgery and chemotherapy) can help prevent breast cancer from coming back in people with high-risk triple negative breast cancer. About 474 participants who had already completed curative t…

This study tested two drugs together (ladiratuzumab vedotin and pembrolizumab) in 185 people with advanced triple-negative breast cancer that had spread. The main goals were to check side effects and see if the combination shrinks tumors. The results help doctors understand if th…

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps people with triple negative breast cancer. Over 1,100 participants received either pembrolizumab or a placebo with chemo before surgery, then continued the same drug alone after s…

This early-phase study tested a new drug called boserolimab, given alone or with pembrolizumab, in 182 adults with advanced solid tumors (including lung and breast cancers). The main goals were to check safety and how the drug moves through the body. Participants received treatme…

This study tested whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps people with advanced triple-negative breast cancer that came back within a year of prior treatment. About 595 participants received either the drug combo or a placebo plus chemo. T…

This study tested whether a combination of two drugs (olaparib and pembrolizumab) works better than standard chemotherapy for people with advanced triple-negative breast cancer that cannot be removed by surgery. About 462 participants who had already benefited from initial treatm…

This early-phase study tested a new drug (TAK-676) combined with pembrolizumab after radiation in 34 adults with lung, triple-negative breast, or head/neck cancers that had stopped responding to standard treatments. The main goals were to check safety, side effects, and find the …